Thousand Oaks Biopharmaceuticals
PrivateLast Round
Series D
Dec 28, 2021
Est. Valuation
$1.33B
Total Funding Raised
$405.9M
Company Overview
Thousand Oaks Biopharmaceuticals is a biotechnology company that offers contract development and manufacturing organization (CDMO) services, enabling partners to provide accessible and affordable biologics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Pharma Supply Chain, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Thousand Oaks Biopharmaceuticals Comparables
Compare Thousand Oaks Biopharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| WuXi Biologics | 87% | |
| Chime Biologics | 86% | |
| MabPlex International | 85% |
Thousand Oaks Biopharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Dec 28, 2021 | ||||
| Series C | Mar 10, 2021 | ||||
| Series B | Jul 23, 2020 | ||||
| Series A | Jan 3, 2019 |
Thousand Oaks Biopharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HighLight Capital | Series C |
| New Alliance Capital | Series A |
| CDH Investments | Series C |
| CCIC Capital | Series C |
| 中信金石投资有限公司 | Series C, Series D, Series B |
| CDH Baifu | Series D |
| Hillhouse Investment | Series D, Series B, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 10, 2021
$61M round led by China Reform Fund Management and Hillhouse Investment.
Thousand Oaks Biopharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Thousand Oaks Biopharmaceuticals's valuation, stock price, and market status.
Is Thousand Oaks Biopharmaceuticals a public or private company?
Thousand Oaks Biopharmaceuticals is a private company.
What is the current stock price of Thousand Oaks Biopharmaceuticals?
Thousand Oaks Biopharmaceuticals is a private company with no public stock price. No recent secondary market data is available.
How much is Thousand Oaks Biopharmaceuticals worth (valuation)?
Valuation information for Thousand Oaks Biopharmaceuticals is not publicly available.
Can I buy Thousand Oaks Biopharmaceuticals stock?
Thousand Oaks Biopharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Thousand Oaks Biopharmaceuticals's last funding round?
Thousand Oaks Biopharmaceuticals's most recent funding round was Series C on March 10, 2021.
Who are the main investors in Thousand Oaks Biopharmaceuticals?
Key investors in Thousand Oaks Biopharmaceuticals include New Alliance Capital, Hillhouse Investment.
Will Thousand Oaks Biopharmaceuticals IPO soon?
No public IPO plans have been announced for Thousand Oaks Biopharmaceuticals.
How can I track Thousand Oaks Biopharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Thousand Oaks Biopharmaceuticals's secondary market activity and sign up for updates.